Analyze SUPN

ShareShare on WhatsApp Share on Facebook Share on X

Equity Research · Deep diveIT-2026-SUPN · 2026-07-30

Supernus Pharmaceuticals, Inc. (SUPN)

HealthcareDrug Manufacturers - Specialty & GenericNasdaqGMMarket cap $2.70B

$46.57

-2.43%

Analyst-style PDF, emailed within minutes

53/100

Mixed picture

Automated weighted score · not a recommendation

Price source: Yahoo · live price · as of 23:00 · Data: Yahoo · SEC EDGAR · FINRA · Wikidata

About the company

Market cap

$2.70B

P/E

—

Beta

0.54

Employees

778

Sector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: NasdaqGMCountry: United StatesFounded: 2005 Website

What the company does

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Day range

$46.08$48.00

52-week range

$32.83$59.68

Price alert on SUPN

Get an in-app and mobile alert every time SUPN crosses a price you set.

Loading short data…

SUPN · Chart

Loading chart…

SMA20 SMA50 SMA200

Charts by TradingView

Support & resistance

Key trading levels, by timeframe

Day

Swing

Computing levels…

The technical signal compass

Sign up free and build your own trading bot with full backtesting. Live bots, real-time alerts and the bot gallery — with a Pro subscription.

Free sign-up

Supernus Pharmaceuticals, Inc. (SUPN) is trading around $46.57 (-2.43% on the last session). Its 52-week range runs from $32.83 to $59.68. Technically: 1 buy signals, 6 sell and 5 neutral. It belongs to the Healthcare sector (Drug Manufacturers - Specialty & Generic) and a 3B$ market cap. Data sourced from Yahoo · live price as of 23:00. This is data analysis only, not advice or a recommendation.

SUPN stock FAQ

What is SUPN's current price?

SUPN is trading around $46.57 (-2.43%), as of 23:00 per Yahoo · live price.

What is SUPN's 52-week price range?

Over the last 52 weeks SUPN ranged between a $32.83 low and a $59.68 high.

Which sector does SUPN belong to?

SUPN belongs to the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

Disclosure & disclaimer: All information, scores, signals and trade plans on this site are produced by an automated algorithmic system and are based on technical and quantitative data only. They do not constitute investment advice, investment marketing or a recommendation to act, and are not a substitute for personal advice from a licensed professional that accounts for your needs and circumstances. We are not investment advisors. Trading securities involves substantial risk, up to the loss of your entire investment; every decision and action is your sole responsibility. i-trade and its operators bear no liability for any direct or indirect damage arising from reliance on this information.

0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ %€ ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇% ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲₿ $ $ ₿ ▼ 0 % ↑ 買 0 0 買 ↑ % 0 ▼ ₿ $ $ ₿ ▼ 01 ◇ ◇ 1 1 # 売 ▲ € ↓ ↓ € ▲ 売 # 1 1 ◇ ◇ 1 1 #$ ↑ ↑ $ % 買 ₿ 0 0 ▼ ▼ 0 0 ₿ 買 % $ ↑ ↑ $ % 買◇ ▲ ▲ ◇ 売 € 1 # ↓ 1 1 ↓ # 1 € 売 ◇ ▲ ▲ ◇ 売 €↑ 0 0 ↑ ₿ 0 $ 買 ▼ % % ▼ 買 $ 0 ₿ ↑ 0 0 ↑ ₿ 0▲ # # ▲ 1 ↓ ◇ € 1 売売 1 € ◇ ↓ 1 ▲ # # ▲ 1 ↓0 買買 0 $ ▼ ↑ 0 % ₿ ₿ % 0 ↑ ▼ $ 0 買買 0 $ ▼# € € # ◇ 1 ▲ ↓ 売 1 1 売 ↓ ▲ 1 ◇ # € € # ◇ 1

Building the strategy

SUPN stock FAQ

What is SUPN's current price?

SUPN is trading around $46.57 (-2.43%), as of 23:00 per Yahoo · live price.

What is SUPN's 52-week price range?

Over the last 52 weeks SUPN ranged between a $32.83 low and a $59.68 high.

Which sector does SUPN belong to?

SUPN belongs to the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

Analyze SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

About the company

SUPN · Chart

Support & resistance

The technical signal compass

SUPN stock FAQ

Supernus Pharmaceuticals, Inc. (SUPN)

About the company

SUPN · Chart

Support & resistance

The technical signal compass

SUPN stock FAQ

Income statement analysis

Institutional & insider data

Full analyst coverage